JP2015520165A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520165A5
JP2015520165A5 JP2015512903A JP2015512903A JP2015520165A5 JP 2015520165 A5 JP2015520165 A5 JP 2015520165A5 JP 2015512903 A JP2015512903 A JP 2015512903A JP 2015512903 A JP2015512903 A JP 2015512903A JP 2015520165 A5 JP2015520165 A5 JP 2015520165A5
Authority
JP
Japan
Prior art keywords
salt
compound
formula
process according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015512903A
Other languages
English (en)
Japanese (ja)
Other versions
JP6196294B2 (ja
JP2015520165A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/041687 external-priority patent/WO2013173779A1/en
Publication of JP2015520165A publication Critical patent/JP2015520165A/ja
Publication of JP2015520165A5 publication Critical patent/JP2015520165A5/ja
Application granted granted Critical
Publication of JP6196294B2 publication Critical patent/JP6196294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015512903A 2012-05-17 2013-05-17 アミノ酸化合物を製造するためのプロセス Active JP6196294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648534P 2012-05-17 2012-05-17
US61/648,534 2012-05-17
PCT/US2013/041687 WO2013173779A1 (en) 2012-05-17 2013-05-17 Process for making amino acid compounds

Publications (3)

Publication Number Publication Date
JP2015520165A JP2015520165A (ja) 2015-07-16
JP2015520165A5 true JP2015520165A5 (enExample) 2016-06-30
JP6196294B2 JP6196294B2 (ja) 2017-09-13

Family

ID=48483247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512903A Active JP6196294B2 (ja) 2012-05-17 2013-05-17 アミノ酸化合物を製造するためのプロセス

Country Status (21)

Country Link
US (1) US9278917B2 (enExample)
EP (1) EP2850054B1 (enExample)
JP (1) JP6196294B2 (enExample)
KR (1) KR102074535B1 (enExample)
CN (1) CN104520263B (enExample)
AU (1) AU2013262516B2 (enExample)
BR (1) BR112014028585B1 (enExample)
CA (1) CA2873658C (enExample)
ES (1) ES2668477T3 (enExample)
HR (1) HRP20180948T1 (enExample)
IL (1) IL235630A (enExample)
MA (1) MA37751B1 (enExample)
MX (1) MX350443B (enExample)
MY (1) MY171538A (enExample)
NZ (1) NZ702939A (enExample)
PL (1) PL2850054T3 (enExample)
RU (1) RU2643146C2 (enExample)
SG (1) SG11201407625WA (enExample)
SI (1) SI2850054T1 (enExample)
TR (1) TR201807444T4 (enExample)
WO (1) WO2013173779A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
DK2861583T3 (en) 2012-05-17 2016-10-03 Array Biopharma Inc METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER
MX354373B (es) 2012-05-17 2018-02-28 Genentech Inc Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
RS60417B9 (sr) 2012-05-17 2021-07-30 Genentech Inc Amorfni oblik aktivnog jedinjenja koje inhibira pirimidinil-ciklopentansko jedinjenje, smeše i njegove metode
SG10201901578UA (en) * 2013-11-15 2019-03-28 Hoffmann La Roche Processes for the preparation of pyrimidinylcyclopentane compounds
US10457648B2 (en) * 2014-09-26 2019-10-29 Genentech Inc. Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) * 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
AU700579B2 (en) 1993-12-12 1999-01-07 Agrogene Ltd A novel method to protect plants from fungal infection
CA2286239A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
JP2003524618A (ja) 1999-03-03 2003-08-19 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害剤
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
EP1636200A2 (en) 2003-06-09 2006-03-22 Boehringer Ingelheim International GmbH Inhibitors of papilloma virus
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
EA020151B1 (ru) 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
DK2861583T3 (en) 2012-05-17 2016-10-03 Array Biopharma Inc METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER
MX354373B (es) 2012-05-17 2018-02-28 Genentech Inc Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
JP2016513112A (ja) 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター
AU2014237198A1 (en) 2013-03-15 2015-11-05 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Similar Documents

Publication Publication Date Title
JP2015520165A5 (enExample)
RU2012103850A (ru) Би-арил-мета-пиримидиновые ингибиторы киназ
JP2011057686A5 (enExample)
JP2013521295A5 (enExample)
JP2009507932A5 (enExample)
JP2007269812A5 (enExample)
JP2018531941A5 (enExample)
JP2012507568A5 (enExample)
JP2006526031A5 (enExample)
ATE383360T1 (de) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
JP2011511933A5 (enExample)
JP2013032389A5 (enExample)
JP2011510079A5 (enExample)
JP2009530282A5 (enExample)
JP2011227454A5 (enExample)
JP2013500304A5 (enExample)
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
MX2009013730A (es) Compuesto amina y uso farmaceutico del mismo.
JP2011522839A5 (enExample)
JP2015518837A5 (enExample)
AR083105A1 (es) Metodo para preparar 2-amino-n-(2,2,2-trifluoroetil)acetamida
MX2007007098A (es) Derivados de pirrol que tienen actividad antagonista del receptor crth2.
RU2014150991A (ru) Способ получения аминокислотных соединений
JP2007526383A5 (enExample)
EP2759540A3 (en) Beta-3 receptor ligands and their use in therapy